RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $18.17 Consensus Target Price from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Hold” from the ten analysts that are covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.17.

RAPT has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. increased its stake in RAPT Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $97,000. EntryPoint Capital LLC purchased a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $161,000. Bank of New York Mellon Corp increased its position in shares of RAPT Therapeutics by 24.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after purchasing an additional 22,175 shares during the last quarter. Finally, Denali Advisors LLC purchased a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $293,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.72 on Monday. The firm has a market capitalization of $60.03 million, a price-to-earnings ratio of -0.55 and a beta of 0.33. The company’s 50-day moving average is $1.98 and its two-hundred day moving average is $3.69. RAPT Therapeutics has a 1-year low of $1.64 and a 1-year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. As a group, equities analysts anticipate that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.